Therapeutic relevance of an EU-GMP certified Cannabis sativa L. strain in a dual in vivo model of cognitive impairment and chronic neuropathic pain

BackgroundAlzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and frequently co-occurs with chronic pain. Worldwide, over 55 million people are affected by AD, with nearly half experiencing persistent pain. Chronic pain has been linked to accelerat...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ivona Costachescu, Raluca-Maria Gogu, Gabriela-Dumitrita Stanciu, Carmen Solcan, Loredana Horodincu, Andrei Szilagyi, Vlad-Constantin Craciun, Daniela-Carmen Ababei, Bogdan-Ionel Tamba
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-02-01
Edice:	Frontiers in Pharmacology
Témata:	Alzheimer’s disease Cannabis sativa L. chronic intermittent therapy comorbidities EU-GMP certification shared neurobiological mechanisms
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1761426/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!